share_log

Spero Therapeutics Shares Are Trading Higher After the Company Announced the Publication of Data From Its Phase 1 Clinical Trial, Which Assessed the Intrapulmonary Pharmacokinetics of SPR719.

Benzinga ·  Oct 3 04:31
Spero Therapeutics Shares Are Trading Higher After the Company Announced the Publication of Data From Its Phase 1 Clinical Trial, Which Assessed the Intrapulmonary Pharmacokinetics of SPR719.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment